Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Javelin Pharmaceuticals said it has been granted a commercially important US patent, enabling protection of its intranasal ketamine drug candidates into 2023.
Subscribe to our email newsletter
Fred Mermelstein, president and founder, said: “Upon approval, PMI-150 will be the only intranasal ketamine product offering physicians and patients a non-opioid alternative for treatment of moderate to severe pain. It will be well-suited for both civilian and military use in medically supervised settings.”
David Bernstein, Javelin’s general counsel and chief intellectual property counsel said: “They are very excited to have this important pharmaceutical composition patent issue, this patent broadens their overall intellectual property portfolio and adds further strength specifically in ketamine. At the same time, it significantly extends the term of commercial exclusivity for Javelin’s intranasal ketamine products.”